Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
This study is currently recruiting participants.
Verified December 2013
by Daiichi Sankyo Inc.
Study NCT01588678 Information provided by Daiichi Sankyo Inc.
First Received on April 26, 2012. Last Updated on December 2, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Solid Tumor
Additional conditions recognized in this trial
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Sponsors listed in this trial
Daiichi Sankyo Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers